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Background: Alcohol abuse comes with risks for increased morbidity and mortality among patients with HIV. This
study aims to determine the prevalence of alcohol use and other risk factors in a sample of primary care patients
with HIV in South Africa and to assess a brief intervention to reduce the use of alcohol in this group.
Methods/Design: A single-blinded randomized controlled trial is designed to determine the efficacy of a brief
intervention to reduce hazardous alcohol use in patients with HIV. The study will be carried out on out-patients
with HIV in two primary healthcare HIV clinics near Pretoria, South Africa. Alcohol use will be assessed with the
Alcohol Use Disorder Identification Test questionnaire. Other data that will be collected relate to health-related
quality of life, depression, sexual behavior, internalized AIDS stigma, HIV-related information and adherence to
antiretroviral therapy (self-reported 7-day recall of missed doses, Visual Analog Scale and pill count). The
intervention consists of a brief counseling session to reduce alcohol risk; the control group receives a health
education leaflet.
Discussion: The findings will be important in the public health setting. If the intervention proves to be efficient, it
could potentially be incorporated into the HIV care policy of the Ministry of Health.
Trial registration: Pan African Clinical trial Registry: PACTR201202000355384
Keywords: Alcohol, HIV, South Africa, InterventionBackground
The use of alcohol in South Africa is among the highest
in Africa [1] with a total adult per-capita consumption
of 9.5 l pure alcohol per year, and a consumption of
34.91 l pure alcohol per year (men 39.64 l, women 23.84 l)
among people that drink alcohol [2]. Since South Africa
also has one of the highest prevalences of HIV in the
world (prevalence estimated to be 17.8% among adults
aged 15 to 49 in 2009) [3], it is possible that a considerable
number of persons living with HIV engage in hazardous* Correspondence: dhuisintveld@itg.be
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distribution, and reproduction in any mediumor harmful alcohol use. Hazardous drinking is defined
as a quantity or pattern of alcohol consumption that
places patients at risk for adverse health events, while
harmful drinking is defined as alcohol consumption
that results in adverse events (for example, physical or
psychological harm) [4]. Prevalence data on (hazardous)
alcohol use in patients with HIV in Africa vary since
different measuring tools were used in different study
populations. A systematic review by Nakimuli-Mpungu
and colleagues on alcohol use, depression and adherence
to antiretroviral therapy (ART) in patients with HIV
showed a prevalence of alcohol use between 2.5 and 51%.
The prevalence of alcohol use disorders ranged from 2.5
to 31% [5]. Myer and colleagues reported a prevalence ofentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Cape Town [6].
Studies in several African countries have shown a
causal link between alcohol use and HIV, and have
shown that alcohol use has effects on the course of HIV,
including adherence to ART. The prevalence of HIV is
considerable higher in adults who have a history of alco-
hol consumption or frequently use alcohol than in adults
who do not use alcohol [7-10]. A systematic review and
meta-analysis by Fisher and colleagues confirmed the
strong association between alcohol use and HIV infec-
tion [11].
The negative effects of alcohol use on the individuals
are numerous. High alcohol use is associated with high-
risk sexual behavior and risk of HIV [12,13]. Once indi-
viduals are infected with HIV, alcohol use is related to
low participation in prevention mother-to-child trans-
mission (PMTCT), pre-test and post-test counseling (in-
cluding returning for test results) [14,15]. Overall, there
is a late presentation to HIV care in patients that use al-
cohol, compared with those that do not use alcohol
(odds ratio = 3.55, 95% confidence interval = 1.63 to
7.71) [16]. Adherence to ART is poor if alcohol is used
[17-21].
HIV disease progression is accelerated by alcohol use,
which is shown by a more likely decline of CD4 T cells
to ≤200 cells/μl and a more frequent detectable viral
load in frequent alcohol users, independent of baseline
CD4 cell count and HIV viral load, ART use over time,
the time since HIV diagnosis, and age and gender [22-24].
Alcohol use can cause liver problems, which could add to
the risk of toxicity in patients using ART.
Screening and brief intervention for alcohol reduction
in primary care patients has proven effective in reducing
alcohol consumption at 6 and 12 months [25]. Results
from studies on screening and brief intervention in HIV
patients using alcohol, mainly performed in the USA,
are not conclusive. One study performed in New York
showed improvement in self-report and biological mar-
kers (CD4 cell count and HIV viral load) after an eight-
session behavioral intervention after 3 months. However,
this result was not sustained at 6 months [26]. A multi-
component (including behavioral) intervention showed
no significant differences in adherence, CD4 count, viral
load or alcohol consumption [27].
Very few reports from resource-limited settings have
been published on interventions to reduce alcohol use in
HIV-positive patients. One study describes an interven-
tion based on a culturally adapted, six-session (over a
3-month period) cognitive-behavioral therapy to reduce
alcohol use among HIV-infected outpatients in western
Kenya, whereby the percentages of days abstinent from
alcohol before session 1 were 52 to 100% for women and
21 to 36% for men. By session 6 this was 96 to 100% forwomen and 89 to 100% for men. The percentages of days
abstinent from alcohol effect sizes (Cohen’s d) between
the first and last cognitive-behavioral therapy sessions
were 2.32 for women and 2.64 for men [28].
This study will measure the prevalence of alcohol use
in patients with HIV and assess the efficacy of a brief




The first part of the study will be a screening phase to
estimate the prevalence of (hazardous and harmful) alco-
hol use in the study population. The study design for the
efficacy study is a single-blinded randomized controlled
trial where information will be collected from patients at
inclusion (before the intervention, which is performed in
the same session: pre-intervention) and at follow-up of 3
and 12 months.
Setting, study population and participants
The sample will include out-patients with HIV at the pri-
mary care clinics in townships in Gauteng, South Africa.
Out-patients with HIV will be screened for hazardous
and harmful alcohol use. Patients identified as ha-
zardous drinkers (on the Alcohol Disorder Identifica-
tion Test (AUDIT) questionnaire) will be randomized
into an intervention group or a control group.
Aim of the study
The aim of the study is to assess the prevalence and se-
verity (hazardous and harmful) of alcohol use in patients
with HIV and its associated factors, and to study the effi-
cacy of a brief intervention for hazardous alcohol use in
out-patients with HIV in primary health care clinics in
townships in South Africa.
Objectives
The objectives of the screening phase are: to measure
the prevalence of alcohol consumption among out-
patients with HIV; and to describe drinking patterns,
health status, quality of life, sexual behavior and adhe-
rence levels among out-patients with HIV, and identify
hazardous drinkers needing intervention.
The objectives of the intervention phase are: to compare
the level of alcohol consumption, health status, quality of
life, level of adherence to ART and sexual behavior among
hazardous drinkers between pre-intervention and 3 and
12 months after the intervention; and to compare levels of
and changes in alcohol consumption, adherence level to
ART, quality of life, health status and number of patients
with virological and immunological failure, between inter-
vention and control groups at 3 and 12 months.
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Hazardous drinkers with HIV in the intervention group
will reduce alcohol drinking more than those in the con-
trol group. In patients that reduce alcohol use, a positive
effect will be seen in adherence levels to ART, quality of
life, health status and virological and immunological
response.
Inclusion criteria
Patients who are 18 years and older, with HIV-1 infec-
tion and who are visiting selected outpatient clinics for
their HIV care will be eligible for this study. Patients
with hazardous alcohol use will be selected using the
AUDIT questionnaire (hazardous drinkers score 8 to 19
for men and 7 to 19 for women).
Exclusion criteria
Patients with mental impairment, patients already
undergoing alcohol reduction treatment and pregnant
women will be excluded from this study.
Sample size calculation
The sample size was calculated using Open Epi [29].
Based on the current AUDIT score of 12 among HIV
patients, it is assumed that the intervention will reduce
the current AUDIT score by 12% to 10.6 [30,31]. Based
on this assumption, the estimated sample size will allow
us with 80% power (5% level of significance) to detect
the difference of 12% between the two groups. This will
give a minimum of 99 patients per arm. It is expected
that 20% of participants may be lost prior to completing
the 3-month and 12-month follow-up assessments so
that the final sample would be 120 per arm. A total of
240 HIV patients (with AUDIT scores 8 to 19 for men
or 7 to 19 for women) will be recruited for the study.
Randomization
Patients fulfilling criteria for selection for this study
will be randomized to receive an intervention or to be
in the control group. Randomization will be done by
concealed, centrally allocated, computer-generated ran-
dom numbers.
Procedure
All consecutive HIV-positive patients visiting two out-
patient clinics will be asked to provide informed consent
to receive a baseline assessment (using the data collec-
tion instruments) and screening for alcohol problems. If
eligible – meaning an AUDIT questionnaire score of 8
to 19 for men or 7 to 19 for women – a second
informed consent will be asked before randomization
into the intervention or control group. Patients with a
score of 20 and above on the AUDIT (with probable
alcohol dependence) will be referred for furthermanagement (according to local standard procedures).
The research assistant nurse will randomize patients by
checking the random numbers that allocate the case to
the intervention arm or control arms. The intervention
or control procedures will be carried out in all patients,
after which they will be followed up at 3 and 12
months (which are standard visit intervals for the
follow-up of the HIV care). The research assistant per-
forming the follow-up assessments will be blinded to
the intervention allocation of the participant. In the
event of a drop-out, at least six individual attempts will
be made to contact patients by telephone and letter.
Even if a contact was not successful at either follow-up
point, further attempts will be made at any next
follow-up point. Sampling will occur throughout all
hours of clinic operation over a 3-month period.
Patients will be offered a drink (soda, juice) during the
interviews.
Data collection instruments
Eight instruments (questionnaires) will be used to collect
data. All questionnaires will be administered in English or
Tswana, the two languages predominantly spoken by
nearly all clinic patients. The questionnaires will be admi-
nistered at baseline and every follow up visit.
Sociodemographic characteristics
A researcher-designed questionnaire will be used to re-
cord information on participants’ age, gender, population
group, language, educational level, marital status, highest
educational qualification, source of income and residen-
tial status.
Health-related quality of life
The WHOQoL-HIVBREF is based on the WHOQOL-
HIV measure, one of the two World Health Organization
(WHO) quality-of-life instruments for the use in HIV-
infected populations [32,33]. The WHOQoL-HIVBREF
evaluates the quality of life in six domains and 31
questions.
Depression
Symptoms of depression will be assessed using the 10-
item version of the Centers for Epidemiologic Studies
Depression Scale [34]. The Centers for Epidemiologic
Studies Depression Scale has been widely used in studies
on the relationship between HIV and depression [35].
The sensitivity and specificity of the Centers for Epide-
miologic Studies Depression Scale 20-item survey has
been reported to average 80% and 70%, respectively,
compared with formal diagnostic interview [36]. We will
also identify patients who experience more severe de-
pressive symptoms by distinguishing those scoring ≥15
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pression Scale 10-item survey [34].
Sexual behavior
To study the sexual behavior of HIV patients, and spe-
cifically those who consume hazardous amounts of alco-
hol before and after intervention, we included questions
on sexual behavior.
Internalized AIDS stigma
We will use the seven-item internalized AIDS-related
stigma scale for people infected with HIV. Items reflect
self-defacing beliefs and negative perceptions of people
living with HIV/AIDS. In previous studies including
South Africa, with the same scale, a Cronbach alpha re-
liability coefficient of 0.72 to 0.76 was found [37].
Alcohol consumption
The 10-item AUDIT assesses alcohol consumption level
(three items), symptoms of alcohol dependence (three
items), and problems associated with alcohol use (four
items) [38]. Responses to items on the AUDIT are rated
on a four-point Likert scale from 0 to 4, with a maxi-
mum score of 40 points. AUDIT scores higher than 19
indicate more severe levels of risk; scores of 8 to 19 in
men and 7 to 19 in women indicate a tendency to prob-
lematic drinking. The AUDIT shows excellent sensitivity
and specificity in detecting Mini-International Neuro-
psychiatric Interview-defined dependence/abuse (area
under the receiver-operating characteristic curve = 0.96)
in HIV patients in South Africa [5].
To reduce the stigma of alcohol use, the WHO sug-
gests integrating the screening of alcohol use with
screening for other health-related behaviors [38]. For
this reason, two questions will be asked on the use of
tobacco products and anthropometric measurements
will be taken to assess the risk factor of overweight
(height, weight and waist circumference).
HIV-related information
A researcher-designed patient information extraction
sheet will be used to record information related to the
HIV infection and will include questions about date of
first positive HIV test, start date for ART, ART regimen,
co-infections and co-medication. The patient file will be
used to obtain additional information. The computerized
laboratory data system will be used to obtain the labora-
tory results. At follow-up, CD4 cell counts and viral load
will be obtained from the computerized laboratory data
system.
Assessment of adherence to antiretroviral therapy
For assessing adherence to ART we will use three tools.Self-reported adherence by recall of missed doses
during last 7 days This tool is easy to use and is signifi-
cantly associated with virological and immunological
outcomes [39].
Visual Analog Scale The 30-day Visual Analog Scale
provides an overall adherence assessment for a 1-month
period. The Visual Analog Scale has been validated in
resource-limited settings [40,41]. Adherence levels
assessed from the Visual Analog Scale are defined as fol-
lows: full adherence, 100%; partial adherence, between
≥95% and <100%; and non-adherence, <95% of pre-
scribed doses taken in the past 30 days. The Visual Ana-
log Scale will be assessed at baseline for patients who
are already on ART and at any follow-up visit if the pa-
tient is on ART.
Pill count A pill count compares the number of pills that
were dispensed and that are remaining at the pill count. A
percentage of adherence to ART will be calculated.
Interventions
Control group
Patients in the control group will only receive a health
education leaflet on responsible drinking. They will re-
ceive the brief intervention only after 12-month follow-
up, if the intervention has proven to be successful.
Intervention group
Patients in the intervention group will first receive per-
sonalized feedback on the AUDIT results. A health edu-
cation leaflet on responsible drinking will then be given
and discussed. Subsequently, simple advice and brief
counseling on reducing excessive drinking will be offered
during a one-session, 20-minute intervention. Since
there is a serious lack of resources in South Africa in
HIV care, an efficient intervention has to be short and
simple to incorporate into daily practice. Intervention
methods whereby patients have to come back for more
sessions might in daily practice be unsuccessful because
of the time-consuming aspect for those who perform the
intervention and because of an expected high patient
drop-out rate. A short, one-session intervention has
therefore been chosen to be tested in this trial. The brief
intervention is based on the WHO brief intervention
package for hazardous and harmful drinking [42], which
is based on the Information–Motivation–Behavioural
Skills Model. The steps of brief counseling are: identify
any alcohol-related problems mentioned in the inter-
view; introduce the sensible drinking leaflet, and
emphasize the idea of sensible limits, and make sure that
patients realize that they are in the medium-risk drink-
ing category; work through the first three sections of the
problem-solving manual while mentioning the value of
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cards; identify a helper; and mention the 3-month and
12-month follow-up.
Counselor training and intervention quality assurance
The intervention research assistants will be trained to
deliver the interventions to the patients. The training
consists of role play, general skills training techniques
and training on HIV and sexual-related issues. A com-
prehensive manual for the brief intervention is available
and will be used to guide the counseling session. The
sites will be visited twice a week by one of the investiga-
tors to observe whether there is adherence to the proto-
col and to offer support and supervision to the research
assistants. During regular research meetings, occurring
problems will be discussed and solved.
Data analysis
Virological failure will be defined according to the defi-
nition in the South African national guidelines on HIV:
a repeat HIV viral load ≥1,000 copies/ml after intense
adherence assessment [43]. Immunological failure will
be defined according to the WHO definition: a fall of CD4
cell count to pre-therapy baseline (or below), or a 50% fall
from the on-treatment peak value (if known), or a per-
sistent CD4 cell count level below 100 cells/mm3 [44].
Means, standard deviations, and percentages will be
used for descriptive statistics. To examine differences
between groups, the t test for continuous data and the
chi-square test for categorical data will be used. General-
ized linear model repeated measures 2×3 analysis of
variance will be used for comparing observations (alcohol
use score) across the three contact periods to demonstrate
a treatment intervention×time interaction. To avoid pos-
sible bias from excluding patients with missing values, pat-
terns of missing values will be analyzed. Multiple
imputation methods using generalized estimating equating
methods, based on all data available in the model, using
five imputed datasets, will be used to impute missing data
at all contact points (baseline and follow-up at 3 and 12
months). SPSS for Windows version 18.0 (SPSS, Inc.,
Chicago, IL, USA) will be used for calculations.
Outcomes
The findings will be important in the public health set-
ting. The AUDIT screening tool has been developed by
the WHO and proved to be applicable in a wide range
of settings and target groups, including HIV patients in
South Africa. The brief intervention we propose was also
developed by the WHO and was proven to be successful
in different settings [42]. This makes the intervention
widely applicable in different settings and regions. How-
ever, the intervention was never tested among patients
with HIV infection in South Africa, which this trial aimsto do. If the intervention proves to be efficient, it could
potentially be incorporated in the South African HIV
care guidelines. The generalizability of the trial result
may not be extended to other countries, however, where
there might be different patterns of alcohol consumption
and different cultural beliefs regarding alcohol use and
medical care.
Trial status
Patients are currently being recruited for the trial.
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